Yes, cephalexin has good activity against gram-positive cocci, specifically staphylococci and streptococci.
Cephalexin, as a first-generation cephalosporin, demonstrates excellent coverage against methicillin-susceptible Staphylococcus aureus (MSSA) and beta-hemolytic streptococci, making it a reliable choice for skin and soft tissue infections caused by these gram-positive cocci. 1
Spectrum of Activity Against Gram-Positive Cocci
The FDA-approved indications for cephalexin explicitly include infections caused by:
- Staphylococcus aureus (including penicillinase-producing strains, but NOT methicillin-resistant strains)
- Streptococcus pyogenes (Group A Streptococcus)
- Streptococcus pneumoniae (penicillin-susceptible strains only) 1
Multiple clinical practice guidelines from the Infectious Diseases Society of America confirm that first-generation cephalosporins like cephalexin have "good activity against staphylococci and streptococci" 2. This is consistently noted across guidelines for skin and soft tissue infections, bite wounds, and other common infections.
Clinical Efficacy Data
Research demonstrates that cephalexin maintains cure rates of 90% or higher for streptococcal and staphylococcal skin infections, with 12 years of clinical experience showing no diminished efficacy 3. In a 1989 study of 317 clinical isolates, cephalexin showed 52.7% sensitivity against gram-positive cocci, though it was less effective than cefazolin (71.8%) or cefotaxime (62.7%) 4.
More recent real-world evidence from a 2026 study of 230 patients with respiratory tract and skin infections showed that cephalexin (combined with clavulanate) achieved clinical success in 100% of upper respiratory tract infection cases and 98.3% of uncomplicated skin and soft tissue infections 5.
Important Limitations and Caveats
Critical gaps in coverage:
- Methicillin-resistant Staphylococcus aureus (MRSA) - completely resistant 1
- Enterococci (including Enterococcus faecalis) - resistant to all cephalosporins 6, 1
- Penicillin-resistant Streptococcus pneumoniae - usually cross-resistant to beta-lactams including cephalexin 1
The Lyme disease guidelines specifically note that "first-generation cephalosporins, such as cephalexin, are inactive in vitro against B. burgdorferi and are ineffective clinically" 6, highlighting that not all gram-positive organisms are covered.
Practical Dosing Considerations
For skin and soft tissue infections, standard dosing is 500 mg orally 3-4 times daily in adults 2. However, emerging pharmacokinetic/pharmacodynamic data suggests that higher doses may be needed for moderate-to-severe infections, especially those caused by Staphylococcus aureus 7. In pediatric bone and joint infections, high-dose cefalexin at 45 mg/kg (maximum 1.5 g) three times daily has shown 99% cure rates with good tolerability 8.
When to Choose Cephalexin vs. Alternatives
Cephalexin is appropriate as first-line therapy when:
- The infection is likely caused by MSSA or streptococci (not MRSA)
- The patient has no severe penicillin allergy (though minor reactions may be acceptable)
- Enterococcal coverage is not needed
For infections where MRSA is suspected or confirmed, vancomycin, daptomycin, or linezolid should be used instead 9, 10. For enterococcal infections, ampicillin or vancomycin-based regimens are required 10.